Publications

Malaria remains a major global public health challenge, with an estimated 247 million cases and 619,000 deaths in 2021, predominantly affecting children in sub-Saharan Africa. Efforts to develop an effective malaria vaccine have spanned over a century, with significant progress achieved in the last two decades. Vaccines such as RTS, S/AS01 (Mosquirix®), PfSPZ Vaccine, and R21/Matrix-M target different stages of the Plasmodium life cycle, including pre-erythrocytic, erythrocytic, and transmission stages. Despite advances, achieving high and durable efficacy has been hampered by the complex parasite life cycle, antigenic variation, and immunological challenges. Clinical trials have demonstrated modest protective efficacy, with generally favorable safety profiles. Ongoing research emphasizes novel vaccine platforms, combination vaccines, adjuvant optimization, and strategies to enhance immune responses across multiple parasite stages. Public-private partnerships, ethical oversight, community engagement, and robust regulatory frameworks remain critical to ensuring equitable access and successful implementation. Continued innovation in vaccine design and delivery is essential to reduce malaria morbidity and mortality and to advance global malaria eradication efforts.